brl-101
Cell therapyexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2022 (NCT05577312)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06300723 | N/A | Jul 29, 2024 | Hacettepe University, Shanghai Bioray Laboratory Inc. |
| NCT06287086 | N/A | Jun 14, 2024 | Shanghai Bioray Laboratory Inc. |
| NCT06287099 | N/A | Apr 20, 2024 | Shanghai Bioray Laboratory Inc., Southern Medical University |
| NCT05577312 | Phase 1 | Nov 1, 2022 | Shanghai Bioray Laboratory Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Bioray Laboratory Inc. | For profit | 4 | 4 | 2 | 2022 |
| Hacettepe University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Southern Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1